Latest Breaking News On - Houston research institute - Page 2 : comparemela.com

HU6 for Patients with NAFLD and Elevated BMI, with Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc discusses results from the phase 2a trial of HU6 and explains its significant impact on liver fat and body weight.

United statesMazen noureddinRivus pharmaceuticals onHouston research instituteRivus pharmaceuticalsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisBody mass indexPhase 2a

Phase 2a Study of HU6, Rivus Pharmaceuticals Investigational Controlled Metabolic Accelerator, Demonstrates Clinical Benefit in Patients with High Body Mass Index and Nonalcoholic Fatty Liver Disease

Phase 2a Study of HU6, Rivus Pharmaceuticals Investigational Controlled Metabolic Accelerator, Demonstrates Clinical Benefit in Patients with High Body Mass Index and Nonalcoholic Fatty Liver Disease
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesAlana rocklandMazen noureddinRivus pharmaceuticals incPrnewswire rivus pharmaceuticals incRivus pharmaceuticalsHouston research instituteDemonstrates clinical benefitHigh body mass indexNonalcoholic fatty liverLancet gastroenterologyPharmaceuticals incHouston methodist hospitalJayson dallasStudy designControlled metabolic accelerators

HU6 Reduces Liver Fat, Body Weight in Patients with NAFLD with High BMI

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

United statesMazen noureddinShaharyar khanGastroenterol hepatolHouston research instituteRivus pharmaceuticals to presentRivus pharmaceuticalsHouston methodistChief scientific officerDose studyAscending dose studyPresent resultsTrial evaluatingControlled metabolic acceleratorAmerican associationLiver diseases

National Liver Health Awareness Month Highlights the Urgent Need for Liver Disease Prevention |

National Liver Health Awareness Month Highlights the Urgent Need for Liver Disease Prevention |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMazen noureddinPhil newsomeWorld gastroenterology organizationBirmingham biomedical research centreHouston research instituteNational liver health awareness monthFatty liver diseaseWorld gastroenterologyHouston methodist hospitalBiomedical research centre

Phase 2a Study of HU6, Rivus Pharmaceuticals Investigational Controlled Metabolic Accelerator, Demonstrates Clinical Benefit in Patients with High Body Mass Index and Nonalcoholic Fatty Liver Disease

/PRNewswire/ Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardiometabolic health, today announced.

United statesAlana rocklandMazen noureddinPrnewswire rivus pharmaceuticals incHouston research instituteRivus pharmaceuticalsRivus pharmaceuticals incLancet gastroenterologyPharmaceuticals incHouston methodist hospitalJayson dallasStudy designControlled metabolic accelerators